Quantitative Investment Management LLC Increases Holdings in Boston Scientific Corporation $BSX

Quantitative Investment Management LLC grew its holdings in Boston Scientific Corporation (NYSE:BSX) by 128.1% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 213,737 shares of the medical equipment provider’s stock after acquiring an additional 120,019 shares during the quarter. Boston Scientific comprises 1.0% of Quantitative Investment Management LLC’s investment portfolio, making the stock its 18th biggest holding. Quantitative Investment Management LLC’s holdings in Boston Scientific were worth $9,122,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Renaissance Group LLC purchased a new stake in shares of Boston Scientific during the 4th quarter worth approximately $28,064,000. Perigon Wealth Management LLC purchased a new position in shares of Boston Scientific in the 2nd quarter valued at $883,000. Y Intercept Hong Kong Ltd grew its position in shares of Boston Scientific by 148.8% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider’s stock valued at $47,816,000 after buying an additional 670,060 shares during the last quarter. Wealthfront Advisers LLC acquired a new stake in Boston Scientific during the 2nd quarter worth $3,253,000. Finally, PensionDanmark Pensionsforsikringsaktieselskab lifted its position in Boston Scientific by 9.9% in the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock valued at $13,659,000 after acquiring an additional 28,961 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In related news, Director David C. Habiger bought 2,100 shares of the company’s stock in a transaction dated Wednesday, August 5th. The shares were acquired at an average price of $47.59 per share, with a total value of $99,939.00. Following the completion of the acquisition, the director owned 17,160 shares in the company, valued at approximately $816,644.40. This trade represents a 13.94% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael F. Mahoney purchased 186,240 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were bought at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the purchase, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have purchased 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is currently owned by insiders.

Boston Scientific Price Performance

Shares of BSX opened at $46.82 on Monday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. Boston Scientific Corporation has a fifty-two week low of $42.20 and a fifty-two week high of $109.50. The firm has a 50-day simple moving average of $46.56 and a 200-day simple moving average of $56.53. The company has a market capitalization of $67.85 billion, a price-to-earnings ratio of 18.96, a price-to-earnings-growth ratio of 1.02 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities research analysts anticipate that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has initiated a share repurchase program on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

BSX has been the topic of several research reports. BTIG Research dropped their price objective on Boston Scientific from $65.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday, July 29th. Barclays reduced their target price on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a report on Thursday, May 28th. Evercore set a $65.00 price target on Boston Scientific in a research note on Monday, July 6th. Wolfe Research lowered Boston Scientific from an “outperform” rating to a “peer perform” rating in a research report on Friday, May 29th. Finally, Piper Sandler reissued an “overweight” rating and issued a $65.00 price objective on shares of Boston Scientific in a report on Friday, June 12th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus target price of $71.62.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.